Featured SPR Members
July 2016


Dr. Misty Good is a Neonatologist physician-scientist and Assistant Professor of Pediatrics in the Division of Newborn Medicine at Children’s Hospital of Pittsburgh and the University of Pittsburgh School of Medicine. She received her Bachelor’s degree from University of Southern California and earned her Masters of Science while completing medical school at American University of the Caribbean School of Medicine. Dr. Good completed her pediatrics training and chief residency at Children’s Hospital of Illinois at the University of Illinois School of Medicine and completed her Neonatal-Perinatal Medicine and post-doctoral fellowship at Children’s Hospital of Pittsburgh and University of Pittsburgh School of Medicine.

Dr. Good’s laboratory focuses on the cellular and molecular mechanisms involved in the development of the gastrointestinal disease affecting premature infants called necrotizing enterocolitis (NEC). Utilizing a mouse model of NEC, she is dissecting the mechanisms by which breast milk and amniotic fluid prevent the progression of the disease. Dr. Good demonstrated that amniotic fluid inhibits Toll-like receptor 4 mediated pro-inflammatory signaling in the fetal and neonatal intestinal epithelium and prevents NEC via epidermal growth factor (EGF) receptor activation (PNAS, 2012). Furthermore, she has also shown that the EGF in breast milk is responsible for the protective effect against NEC (Mucosal Immunology, 2015). The translational significance of these findings are being actively pursued in her laboratory, as she has developed a premature piglet model of NEC and has begun testing therapeutics in this model (AJP-GI and Liver, 2014). A current focus of her laboratory seeks to better understand the intestinal mucosal host defense involved in NEC pathogenesis, to gain insights that will lead to the development of novel therapeutics for the disease. Additionally, Dr. Good has ongoing translational research studies evaluating the differences in the biological signature of premature infants with and without necrotizing enterocolitis, with the long term goal of advancing the field of NEC research and affording the opportunity to intervene earlier in the disease course, and institute strategies that may prevent the development of this devastating disease altogether.

View Dr. Good's articles in PubMed